Epione Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 08-07-2024
- Paid Up Capital ₹ 0.10 M
as on 08-07-2024
- Company Age 12 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 21.49%
(FY 2023)
- Profit -8.59%
(FY 2023)
- Ebitda -5.30%
(FY 2023)
- Net Worth 47.33%
(FY 2023)
- Total Assets 30.09%
(FY 2023)
About Epione Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Pankaj Sumatilal, Rekha Pankaj, Rushika Vipul, and One other member serve as directors at the Company.
- CIN/LLPIN
U24233PN2012PTC143777
- Company No.
143777
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 Jun 2012
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Pune, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Epione Pharmaceuticals Private Limited offer?
Epione Pharmaceuticals Private Limited offers a wide range of products and services, including Sexual Wellness Products, Fertility Enhancer, Antiparasitic Drug, Ivermectin Tablets.
Who are the key members and board of directors at Epione Pharmaceuticals?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vipul Pankaj  | Director | 29-Nov-2021 | Current |
| Rushika Vipul | Director | 16-Jan-2018 | Current |
| Pankaj Sumatilal | Director | 29-Nov-2021 | Current |
| Rekha Pankaj | Director | 10-Apr-2018 | Current |
Financial Performance of Epione Pharmaceuticals.
Epione Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 21.49% increase. The company also saw a slight decrease in profitability, with a 8.59% decrease in profit. The company's net worth Soared by an impressive increase of 47.33%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Epione Pharmaceuticals?
Unlock access to Epione Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Epione Pharmaceuticals?
Epione Pharmaceuticals has a workforce of 108 employees as of Apr 03, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Epione Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Epione Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
